We found relatively high rates in LUSC (14.3%), HER2+ breast cancer (8.8%), and breast cancer with unknown HER2 status (5.8%), and low rates in LUAD (1.75%) and CRC (1.59%). This evidence concerns the gene ERBB2 and breast carcinoma.